HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Vanlandschoot, P. Articles by Leroux-Roels, G. Search for Related Content PubMed PubMed Citation Articles by Vanlandschoot, P. Articles by Leroux-Roels, G. Agricola Articles by Vanlandschoot, P. Articles by Leroux-Roels, G.

Immunostimulatory potential of hepatitis B nucleocapsid preparations: lipopolysaccharide contamination should not be overlooked

¹ Virus Host Interactions Unit, Center for Vaccinology, Department of Clinical Biology, Microbiology and Immunology, Faculty of Medicine and Health Sciences, Ghent University, De Pintelaan 185, B-9000 Ghent, Belgium
² The Flanders Interuniversity Institute for Biotechnology, Department of Medical Protein Research (VIB9), Faculty of Medicine and Health Sciences, Ghent University, De Pintelaan 185, B-9000 Ghent, Belgium

Correspondence
Peter Vanlandschoot
Peter.Vanlandschoot{at}UGent.be

The nucleocapsid of hepatitis B virus (HBV) allows insertions of heterologous peptides and even complete proteins. Because of its outstanding capacity to induce B-cell, T-helper and cytotoxic T-cell responses, this structure is considered to be an important instrument for future vaccine development. Most of the evidence for the unique immunogenic qualities of nucleocapsids has been generated in mice, which are not natural hosts of HBV. Moreover, most nucleocapsid preparations used in these studies were produced in a recombinant manner in Escherichia coli. Such preparations have been shown to contain lipopolysaccharide (LPS). Not unexpectedly, it is shown here that contaminating LPS, rather than the nucleocapsid structure itself, is responsible for the activation of human antigen-presenting cells. Careful examination of the literature dealing with the immunogenicity of HBV nucleocapsids suggests that the possible presence of LPS has been largely ignored or underestimated in several studies. This raises doubts on some of the underlying mechanisms that have been proposed to explain the unique immunogenicity of the HBV nucleocapsid.

This article has been cited by other articles:

				P. Vanlandschoot, F. Van Houtte, B. Serruys, and G. Leroux-Roels Contamination of a Recombinant Hepatitis B Virus Nucleocapsid Preparation with a Human B-Cell Activator J. Virol., March 1, 2007; 81(5): 2535 - 2536. [Full Text] [PDF]

				D. Gatto, S. W. Martin, J. Bessa, E. Pellicioli, P. Saudan, H. J. Hinton, and M. F. Bachmann Regulation of Memory Antibody Levels: The Role of Persisting Antigen versus Plasma Cell Life Span J. Immunol., January 1, 2007; 178(1): 67 - 76. [Abstract] [Full Text] [PDF]

				P. Vanlandschoot, G. Leroux-Roels, A. Cooper, G. Tal, and Y. Shaul The Role of Heparan Sulfate and TLR2 in Cytokine Induction by Hepatitis B Virus Capsids J. Immunol., November 15, 2005; 175(10): 6253 - 6255. [Full Text] [PDF]

				G. Sen, A. Q. Khan, Q. Chen, and C. M. Snapper In Vivo Humoral Immune Responses to Isolated Pneumococcal Polysaccharides Are Dependent on the Presence of Associated TLR Ligands J. Immunol., September 1, 2005; 175(5): 3084 - 3091. [Abstract] [Full Text] [PDF]

				A. Cooper, G. Tal, O. Lider, and Y. Shaul Cytokine Induction by the Hepatitis B Virus Capsid in Macrophages Is Facilitated by Membrane Heparan Sulfate and Involves TLR2 J. Immunol., September 1, 2005; 175(5): 3165 - 3176. [Abstract] [Full Text] [PDF]